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A B S T R A C T   
Artemisinin resistance (AR) emerged in South East Asia 13 years ago and the identification of the resistance 
conferring molecular marker, Plasmodium falciparum Kelch 13 (Pfk13), 7 years ago has provided an invaluable 
tool for monitoring AR in malaria endemic countries. Molecular Pfk13 surveillance revealed the resistance foci in 
the Greater Mekong Subregion, an independent emergence in Guyana, South America, and a low frequency of 
mutations in Africa. The recent identification of the R561H Pfk13 AR associated mutation in Tanzania, Uganda 
and in Rwanda, where it has been associated with delayed parasite clearance, should be a concern for the 
continent. In this review, we provide a summary of Pfk13 resistance associated propeller domain mutation 
frequencies across Africa from 2012 to 2020, to examine how many other countries have identified these mu-
tations. Only four African countries reported a recent identification of the M476I, P553L, R561H, P574L, C580Y 
and A675V Pfk13 mutations at low frequencies and with no reports of clinical treatment failure, except for 
Rwanda. These mutations present a threat to malaria control across the continent, since the greatest burden of 
malaria remains in Africa. A rise in the frequency of these mutations and their spread would reverse the gains 
made in the reduction of malaria over the last 20 years, given the lack of new antimalarial treatments in the event 
artemisinin-based combination therapies fail. The review highlights the frequency of Pfk13 propeller domain 
mutations across Africa, providing an up-to-date perspective of Pfk13 mutations, and appeals for an urgent and 
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concerted effort to monitoring antimalarial resistance markers in Africa and the efficacy of antimalarials by re- 
establishing sentinel surveillance systems.   
1. Introduction 
Efficacious antimalarial drugs are a critical component of malaria 
control. They rapidly clear the parasite biomass following early detec-
tion of malaria infections, thus reducing the burden of disease. Chloro-
quine (CQ), was a low cost treatment that was the mainstay of 
uncomplicated Plasmodium falciparum malaria treatment for decades. 
CQ resistance and clinical failure was initially observed in South East 
(SE) Asia in the late 1950s along the Thai-Cambodia border, that later 
spread into Africa in the late 1970s and an independent emergence of 
resistance was described in Colombia, South America also in the late 
1950s (Payne 1987; Wellems and Plowe 2001). Thereafter, 
Sulphadoxine-Pyrimethamine (SP) became the preferred, affordable 
alternative to CQ. However resistance to SP quickly emerged, mirroring 
the spread of CQ resistance, emerging in Thailand in the mid 1960s and 
then spreading into Africa (Roper et al., 2004) in the 1990s, with the 
independent emergence of SP resistance in Africa (Pearce et al., 2009) 
and South America (Cortese et al., 2002; Mita et al., 2007). The wide-
spread resistance to SP by the mid 1990s rendered the drug ineffective, 
prompting a policy change in the treatment of uncomplicated malaria to 
artemisinin-based combination therapies (ACTs). Though SP was inef-
fective as a radical cure, it was in use until recently in combination with 
artesunate (WHO Report on antimalarial efficacy, 2020) and is still in 
use as a chemoprophylatic agent in Intermittent Preventive Treatment in 
pregnancy (IPTp) (ter Kuile et al., 2007), IPT in infants (Naidoo and 
Roper 2011) and seasonal malaria chemoprevention (SMC) in the Sahel 
region (WHO, SMC, 2012). The malaria infection prevalence and disease 
burden significantly increased in Africa between 1985 and 2004, and 
although it is not possible to determine the exact contributions, it seems 
plausible that drug resistance was a factor (Snow et al., 2001; Snow 
et al., 2017). In the last 2 decades, there has been a significant decline in 
the malaria disease burden in Africa (WHO Malaria Report, 2020), 
which may be partially attributed to the successful roll out of ACTs from 
2001 onwards. 
2. Molecular markers of resistance 
The ~40 year delay between observing CQ clinical failure to defining 
the molecular marker of resistance meant that tracking resistance was 
initially based on clinical phenotype, limiting monitoring capacities of 
antimalarial resistance to the laborious therapeutic efficacy studies 
(TES) and a >25% treatment failure by day 14 (WHO Report on anti-
malarial efficacy, 2020). Nevertheless, these clinical data provided 
valuable data that prompted the change in antimalarial treatment policy 
in Africa. The subsequent identification of the Plasmodium falciparum 
chloroquine resistance transporter (Pfcrt) gene as the marker for CQ 
resistance in 2000 (Fidock et al., 2000; Djimde et al., 2001), made 
tracking the extent of CQ resistance possible. More recently in East 
(Mwai et al., 2009; Wamae et al., 2019) and Southern (Frosch et al., 
2014) Africa it highlighted a reversion to CQ sensitive parasite pop-
ulations. In Malawi specifically, CQ clinical efficacy has also been 
demonstrated (Laufer et al., 2006). In contrast, SP treatment failure was 
observed in combination with the molecular characterization of resis-
tance conferring mutations (i.e. Plasmodium falciparum dihydrofolate 
reductase (Pfdhfr) triple and Plasmodium falciparum dihydropteroate 
synthase (Pfdhps) double mutants (Dieckmann and Jung 1986; Cowman 
et al., 1988), and when both treatment failure and molecular markers of 
resistance were found to be widespread this prompted the change in 
treatment policy to ACTs. Molecular markers are therefore a valuable 
tool for strengthening resistance monitoring, confirming resistance, 
providing an early warning signal and for assessing resistance trends 
(WHO Report on antimalarial efficacy, 2020). 
3. Artemisinin resistance 
The rapid identification of the artemisinin resistance (AR) molecular 
marker, Plasmodium falciparum kelch 13 (Pfk13) (Ariey et al., 2014), 
only 6 years after the initial observation of ACT clinical failure once 
again in SE Asia along the Thai-Myanmar and Thai-Cambodia borders 
(Noedl et al., 2008; Dondorp et al., 2009), changed the course of sur-
veillance in SE Asia. . The Pfk13 molecular marker made it possible to 
define the foci and origins of the emergence of resistance and its spread 
in the Greater Mekong subregion (Miotto et al., 2015). Initially, C580Y 
and three other loci (Y493H, R539T, I543T) were identified as the ART 
resistance conferring mutations associated with delayed parasite clear-
ance (Ariey et al., 2014). 
The Pfk13 gene encodes a protein containing a conserved N-terminal 
domain followed by a BTB/POZ domain and a 6-blade propeller domain 
at the C-terminal end (Adams et al., 2000; Straimer et al., 2015). The 
validated mutations in the propeller domain associated with ART 
resistance, includes F446I, N458Y, M476I, Y493H, R539T, I543T, 
P553L, R561H, P574L, C580Y and A675V (WWARN 
Genotype-Phenotype Study Group, 2019). These mutations arose inde-
pendently along the Thai-Myanmar and Thai-Cambodia border regions 
and have since spread widely across SE Asia (Tun et al., 2015; Wang 
et al., 2015). Outside SE Asia, Papua New Guinea (Miotto et al., 2020) 
and Guyana (Mathieu et al., 2020) have reported the independent 
emergence of Pfk13 mutations, notably the C580Y mutation. 
In South America, where ACT clinical failure has not yet been 
confirmed, monitoring the Pfk13 gene has allowed for the early identi-
fication of mutations that could potentially result in resistance to arte-
misinin. For instance, in Guyana an indegenious C580Y mutation, has 
been observed at a low frequency (Mathieu et al., 2020). In Africa, 
several studies have identified a number of low frequency Pfk13 pro-
peller domain mutations that are the focus of this brief review that leads 
to a plea to mount a concerted and deliberate approach to monitor Pfk13 
mutations across the continent. 
4. Molecular epidemiology 
Molecular epidemiology is an effective tool for the monitoring and 
tracking of parasite susceptibility to antimalarials, which in combina-
tion with drug efficacy trials enables prompt changes in treatment policy 
before clinical treatment failure negatively impacts control efforts. 
Given the immense success in the tracking the emergence and spread of 
CQ and SP resistant parasite across the globe, we have a robust frame-
work to understand and monitor the spread of AR parasites from SE Asia. 
Furthermore, with a relatively small number of antimalarials in use 
(WHO Report on antimalarial efficacy, 2020) and the importance of 
ACTs to malaria control efforts in Africa, Pfk13 mutants should be 
closely and systematically monitored in Africa. Numerous studies have 
been published examining Pfk13 mutations across the continent (Kamau 
et al., 2015; Kayiba et al., 2020). A recent study conducted by Uwimana 
et al. (2020), between 2012 and 2015 in Rwanda, highlighted the local 
emergence of an ART resistance validated mutation, R561H. They also 
demonstrated through CRISPR-Cas genome editing that the 561H mu-
tation conferred in vitro resistance to ART. In a reversal of fortune, 
molecular surveillance (the detection of the resistance mutation) pre-
ceded the clinical evidence of an association of the R561H resistance 
mutation with delayed parasite clearance (Uwimana et al., 2021). Thus, 
demonstrating that the utility of molecular surveillance is rapid and can 
be conducted at a much larger spatial scale than therapeutic efficacy 
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studies, allowing clinical studies to be targeted in high risk locations. 
Unfortunately, the de novo emergence of ART resistance markers in Af-
rica is a concern, since the spread of resistant parasites across Africa 
would be catastrophic. 
This brief review includes a collation of data from Africa, following 
two recent publications that reported the R561H mutation in Rwanda 
(Uwimana et al., 2020) and Tanzania (Moser et al., 2020). The R561H 
mutation is one of the 10 validated SE Asian AR associated mutations 
(WWARN Genotype-Phenotype Study Group, 2019) (Table 1), raising 
the concern that it may spread and lead to clinical impacts. Fortunately, 
it currently appears at a low frequency, and is limited to three separate 
studies from Rwanda, Tanzania and Uganda (Table 1). We therefore 
examined other African studies with parasite samples collected from 
2012 to date, to determine whether these studies in the continent have 
also identified the R561H mutation or other propeller domain mutations 
that would give an indication of its spread. 
5. Study selection criteria 
We searched the PubMed database for peer reviewed articles from 
malaria endemic African countries published between January 1, 2016 
and November 11, 2020, that had genotyped the Pfk13 gene, focusing on 
propeller domain mutations. The restriction on publication date was to 
enable the review of recent publications that would encompass parasite 
samples overlapping with the Rwandan (Uwimana et al., 2020) and 
Tanzanian (Moser et al., 2020) studies and recent samples, i.e. from 
2012 to date. The following search terms were used: “((malaria OR 
falciparum) AND (molecular marker OR kelch13 OR Pfkelch13 OR K13 OR 
PfK13)) AND ((Africa OR Afrique OR country name [focusing on malaria 
endemic sub-Saharan African countries]) AND (("2016/01/01" [Date - 
Publication]: “2020/11/11" [Date - Publication]))”. Three individuals 
independently screened the articles and excluded studies based on 
genetically modified parasites, reviews, conference proceedings, letters 
of correspondence and modelling studies. Additionally, six individuals 
extracted the following details from the articles: the year samples were 
collected, country of origin, age of study participants, first line ACT 
recommended in the country of origin, genotyping assay, study popu-
lation (asymptomatic or symptomatic), sample size and polymorphisms 
across the propeller domain of the Pfk13 gene. 
6. Summary of the Pfk13 mutations from the extracted literature 
Recently, a systematic review identified Pfk13 mutations across Af-
rica that have been associated with ART resistance, though at low fre-
quencies (Kayiba et al., 2020). Here we present data of Pfk13 propeller 
domain mutations from >70 studies based on the PRISMA guidelines 
(Fig. 1) (Page et al., 2021) undertaken in Africa from samples obtained 
from 2012 to 2020, across 30 countries (Table S1, Full table accessible at 
Harvard Dataverse: https://doi.org/10.7910/DVN/EUPXCF). The Pfk13 
genotypes detected across many African countries were primarily 
wild-type with only Ghana reporting the C580Y mutation (Matrevi et al., 
2019; Aninagyei et al., 2020) associated with the majority of ART 
resistance in SE Asia. There were no Pfk13 mutations reported in Benin 
(2014), The Gambia (2012–2014) and Liberia (2014–2017) (Table S1). 
Only 3 other countries, apart from Rwanda, have reported the R561H 
mutation. In Tanzania, two parasites sampled from 764 were identified 
in 2017 (0.3%) (Moser et al., 2020) and a single parasite from 422 
parasites sampled in 2019 (0.2%) (Bwire et al., 2020), similarly in 
Uganda one parasite was identified from 796 samples in 2018/2019 
(0.1%) (Asua et al., 2020), no clinical failure was observed (consistent 
with the findings in Rwanda). In addition to the R561H mutation, the 
A675V mutation was also identified in four separate studies conducted 
in Uganda, showing an increase in its frequency to 5% in sample sets 
obtained in 2018 and 2019. The A675V mutation has also been 
described in a Rwandan and Nigerian study (Table 1). Only one high 
frequency propeller domain mutation was identified (i.e. A578S), which 
has been detected in 14 countries at frequencies of up to 11%. Another 
high frequency (>5%) Pfk13 mutation outside the propeller domain, 
K189T, has been identified in 8 countries. These high frequency muta-
tions have not been associated with ART resistance or delayed parasite 
clearance. 
The collated data provides an Africa-wide perspective on the current 
status of the prevalence of Pfk13 mutations. The mutations known to be 
associated with delayed parasite clearance (i.e. M476I, P553L, R561H, 
P574L, C580Y and A675V) were observed at low frequencies (<5%) in 
four countries, Ghana, Rwanda, Uganda and Tanzania, indicating that 
we cannot be complacent regarding the potential spread of such muta-
tions in Africa and that data on early signs of potential resistance to ACTs 
are essential. Notably, the data presented in this review is from 30 (67%) 
countries (Table S1) across 45 malaria endemic continental Africa and 
the islands of Madagascar, Sao Tome & Principe and Comoros (WHO 
Malaria Report, 2020), highlighting the paucity of molecular surveil-
lance data and countries to target for future molecular surveys. 
7. Conclusions 
In comparison to the late identification of Pfcrt, Pfk13 was identified 
swiftly after artemisinin clinical failure was observed, due to the rapid 
advances in whole genome sequencing technologies that has revolu-
tionized our ability to detect important mutations. 
Research teams in many African countries are using a wide range of 
techniques from the gold standard Sanger sequencing method through 
to amplicon deep sequencing, molecular inversion probes (MIPs) and 
whole genome sequencing to provide important data on the current state 
of Pfk13 mutation prevalence. Molecular surveillance capacity is present 
in Africa to allow for the roll out of molecular surveillance tools, and 
African institutions have capacity to undertake the laboratory work and 
bioinformatics analyses across the continent. However, these studies are 
largely opportunistic and linked to specific research projects, rather than 
programmatic and linked to public health surveillance initiatives. 
Based on historical evidence of antimalarial resistance to CQ and SP 
emerging in SE Asia and spreading to Africa, it was expected that ART 
resistance was likely to follow the same trajectory and hence the 
numerous studies to genotype Pfk13. However, the data on the de novo 
emergence of resistance mutations emphasize that such studies 
(Table S1) are important to provide a quick overview of mutation fre-
quencies to inform policy decision making. With no new antimalarials 
immediately available, if ACTs fail, this threatens to reverse the signif-
icant gains made in the global reduction in malaria over the last 20 years 
(World Malaria report, 2020). Consequently, this recent detection of 
ART resistance mutations at codons R561H (recently associated with 
delayed parasite clearance), P574L, C580Y and A675V, serves as an 
early warning signal of potential resistance. 
Currently, only 4 countries across malaria-endemic Africa have 
shown evidence of low frequency AR associated mutations, with an early 
indication of indigenous Pfk13 mutations in the East Africa region, 
suggesting that the threat of independent acquisition of resistance 
should be taken as seriously as the threat of imported resistance. The 
data generated come from independent research projects, and hence a 
mechanism to report regularly on findings and interact with national 
and international policy makers has not been defined. There is therefore 
an urgent need for increased, standardized and prospective antimalarial 
resistance molecular surveillance across Africa. 
How to intergrate molecular surveillance and clinical effectiveness to 
support decision making by National Malaria Control Programmes needs 
defining and needs investment in order to stay ahead of the ART resis-
tance curve. Taking lessons from historically successful networks, 
twenty years ago, the East African Network for Monitoring Antimalarial 
Treatment (EANMAT) served as a flagship collaboration between sub- 
regional research scientists and national ministry of health case- 
management implementing and policy staff (EANMAT, 2001; EAN-
MAT, 2003). The network successfully lobbied governments and donors 




Frequencies of k13 validated mutations across Africa from 2012 to date.  
Year Study country Reference Assay N PfK13 mutations frequency % [n] 
F446I M476Ia Y493Ha R539Ta I543Ta P553L R561Ha P574L C580Ya A675V 
2019 Angola Dimbu et al., 2021 Sanger 103           
2014 Benin Ogouyèmi-Hounto et al., 2016 Sanger 78           
2012–2016 Botswana Tawe et al., 2018 Sanger 127           
2014–2017 Cameroon Moukoko et al. 2019 Sanger 175           
2017–2019 Central African Republic Nzoumbou-Boko et al., 2020 Sanger 187           
2015–2016 Congo Mayengue et al., 2018 Sanger 127           
2017 Democratic Republic of Congo Yobi et al., 2020 Sanger 717           
2013–2014 Equatorial Guinea Li et al., 2016 Sanger 98           
2014–2017 Eritrea Pacheco et al., 2019 Amp-Seq 117           
2014 Ethiopia Lo et al., 2017 Sanger 226           
2017–2018 Gabon Adegbite et al., 2019 Sanger 100           
2012–2014 Gambia Amambua-Ngwa et al., 2017 Taq-man/Sanger 184           
2014–2017 Ghana Mensah et al. 2020 MIPs 619      0.2 [1]     
2007–2016 Ghana Matrevi et al. (2019) Sanger 854  0.1 [1]    0.1 [1]   0.1 [1]  
2017–2018 Ghana Aninagyei et al. (2020) WGS 84         3.6 [3]  
2016 Guinea Beavogui et al., 2020 ND 411           
2016 Guinea-Bissau Nag et al., 2019 Amp-seq 97           
2014–2019 Kenya Omedo et al.,. Unpublished data Amp-Seq 284           
2014–2017 Liberia Pacheco et al., 2019 Amp-Seq 21           
2015–2016 Mali Kone et al., 2020 WGS 216           
2015–2017 Mozambique Gupta et al., 2020 Sanger 206           
2013 Niger Laminou et al. 2017 Sanger 366           
2014–2017 Nigeria Pacheco et al., 2019 Amp-Seq 29          3.4 [1] 
2013–2015 Rwanda Uwimana et al. (2020) Sanger 466       4.1 [19] 0.2 [1]   
2014–2015 Rwanda Tacoli et al. 2016 Sanger 147       0.7 [1] 0.7 [1]  0.7 [1] 
2015–2019 Senegal Delandre et al. 2020 Sanger 327           
2016–2017 Somalia Warsame et al. 2019 Sanger 138           
2018 South Africa Raman et al. 2019 Sanger 532           
2015–2017 Sudan Hussien et al., 2020 Amp-Seq 176           
2019 Tanzania Bwire et al. (2020) Amp-Seq 422       0.2 [1]    
2017 Tanzania Moser et al. (2020) MIPs 764       0.3 [2]    
2012–2013 Togo Dorkenoo et al. 2016 Sanger 500           
2012–2016 Uganda Conrad et al. 2019 Sanger 716        0.1 [1]  0.1 [1] 
2016–2017 Uganda Asua et al. 2020 ND 412          1.7 [7] 
2014–2016 Uganda Ikeda et al., 2020 ND 194          0.5 [1] 
2018–2019 Uganda Asua et al. (2020) MIPs 796       0.1 [1]   5.5 [44] 
2017 Zambia Sitali et al. 2020 Sanger 70            
a Represents validated SE Asian artemisinin resistance mutations. N is the number of samples that were successfully genotyped per study. n is the number of samples harbouring the respective mutation. ND = could not 
be determined. Assay represents the genotyping assay used in the respective study i.e. Sanger - Sanger sequencing, MIP - molecular inversion probes, WGS - whole-genome sequencing, Amp-Seq - amplicon sequencing. DR 
Congo stands for the Democratic Republic of Congo. 
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to switch to ACTs that were expected to last for a long time, in 2004, 
however EANMAT has been inactive since 2004. Re-establishing 
sentinel surveillance sites to formulate evidence-based antimalarial 
drug policies through sub-regional technical networks for monitoring 
antimalarial resistance such as EANMAT, West African Network for 
Monitoring Antimalarial Treatment (WANMAT) and Horn of Africa 
Network for Monitoring Antimalarial Treatment (HANMAT) (EANMAT, 
2000; EANMAT, 2001; Talisuna et al., 2006; HANMAT Report 2013), 
would provide an effective framework to combine longitudinal, sentinel 
site surveillance and clinical therapeutic efficacy studies (TES). In 
addition, including the new recommendation of a change in drug policy 
if day 28 or day 42 efficacy falls below 90% in TES (WHO Report on 
antimalarial efficacy, 2020) to transform policy and provide a holistic 
view of antimalarial resistance in Africa. 
Author contributions 
L.N., K.M.K. and K.W. conducted the literature review and drafted 
the manuscript. I.O. V.O. and M.A. conducted the literature review and 
reviewed the manuscript. B.A., A.G., D.S.I., A.A-N., N.D-Q., S.K.T., C.K., 
S.T., A.A.D., and A.D. reviewed the manuscript. J.R. and R.W.S. 
contributed to the literature review and reviewed the manuscript. P.B. 
and L.I.O–O. conceived, drafted and reviewed the manuscript. All au-
thors read and approved the final manuscript. 
Declaration of competing interest 
The authors declare no competing interests. 
Acknowledgements 
The DELTAS Africa Initiative (Grant No. DEL-15-003), an indepen-
dent funding scheme of the African Academy of Sciences (AAS) Alliance 
for Accelerating Excellence in Science in Africa (AESA) and supported by 
the New Partnership for Africa’s Development Planning and Coordi-
nating Agency (NEPAD Agency) with funding from the Wellcome Trust 
and the UK government, DELGEME Grant 107740/Z/15/Z supports K. 
M.K and IDeAL Grant No. 107769/Z/10/Z supported K.W and M.A. The 
views expressed in this publication are those of the author(s) and not 
necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK 
government. RWS is supported as a Wellcome Trust Principal Fellow (# 
212176). LN, KMK, KW, VO, MA, IO, RWS, PB and LIOO are grateful to 
the support of the Wellcome Trust to the Kenya Major Overseas Pro-
gramme (# 203077). L.I.O–O and V.O. are supported by a Wellcome 
Trust Intermediate Fellowship (Grant No. 107568/Z/15/Z awarded to L. 
I.O–O). We also thank the Director of KEMRI for permission to publish 
this article. 
Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.ijpddr.2021.06.001. 
References 
Adams, J., Kelso, R., Cooley, L., 2000. The kelch repeat superfamily of proteins: 
propellers of cell function. Trends Cell Biol. 10, 17–24. 
Fig. 1. Flow diagram of study selection criteria. The diagram indicates the numbers of publications identified in PubMed, manually screened and excluded to settle 
on a list of 86 publications reviewed for this study. An initial screen to exclude reviews, documents, books and meta-analyses was conducted. A further selection 
process was done based on the following non-eligibility criteria to exclude studies that were: reviews, from outside Africa, not examining Kelch 13, non-Plasmodium 
falciparum (Pf), parasite samples collected before 2012, published before 2016 and a low sample size <10 to obtain 76 publications. The 86 publications that met the 
criteria, focusing on kelch 13 mutations in Africa in either a standard research or clinical trial article. 
L. Ndwiga et al.                                                                                                                                                                                                                                 
International Journal for Parasitology: Drugs and Drug Resistance 16 (2021) 155–161
160
Adegbite, B.R., Edoa, J.R., Honkpehedji, Y.J., Zinsou, F.J., Dejon-Agobe, J.C., Mbong- 
Ngwese, M., Lotola-Mougueni, F., Koehne, E., Lalremruata, A., Kreidenweiss, A., 
et al., 2019. Monitoring of efficacy, tolerability and safety of artemether- 
lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated 
Plasmodium falciparum malaria in Lambaréné, Gabon: an open-label clinical trial. 
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